gene

DES

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DES: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

196Connections
29Hypotheses
0Analyses
50Outgoing
50Incoming
19Experiments
0Debates

Summary

DES is a gene implicated in neurodegeneration research. Key relationships include: activates, implicated in, associated with. Associated with ALS, Aging, Als. Connected to 115 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info
Gene SymbolDES
Full NameDesmin
Chromosome2q35
Functionis a critical structural component of muscle cells[@paulin2004].
Molecular Weight53 kDa
Amino Acids470 aa
PathwaysAngiogenesis, Apoptosis, Autophagy, Ferroptosis, Necroptosis
UniProt IDP17661
NCBI Gene ID1674
Ensembl IDENSG00000175084
OMIM125660
GeneCardsDES
Human Protein AtlasDES
N-terminal head domain (residues 1-99)Contains phosphorylation sites and regulates filament assembly
Central rod domain (residues 100-411)Consists of four alpha-helical segments (1A, 1B, 2A, 2B) separated by linkers, responsible for dimerization and filament assembly
Associated DiseasesAging, Als, Alzheimer, Cancer, Cardiac, Cardiovascular
InteractionsAGING, AMPK, AND, APOPTOSIS, App, AUTOPHAGY
KG Connections196 knowledge graph edges
DatabasesGeneCardsHPASTRING
🔮 Predicted Structure: DES — AlphaFold P17661 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

DES Gene

gene · 1159 words

DES Protein

protein · 630 words

Pathway Diagram

graph TD
    DES["DES"]
    SMOC2["SMOC2"]
    DES -->|"co expressed with"| SMOC2
    DSP["DSP"]
    DES -->|"co expressed with"| DSP
    GJA1["GJA1"]
    DES -->|"co expressed with"| GJA1
    myofibrillar_myopathy{"myofibrillar myopathy"}
    DES -->|"causes"| myofibrillar_myopathy
    Aging{"Aging"}
    DES -->|"activates"| Aging
    Ms{"Ms"}
    DES -->|"activates"| Ms
    Cancer{"Cancer"}
    DES -->|"associated with"| Cancer
    Als{"Als"}
    DES -->|"therapeutic target"| Als
    DES -->|"therapeutic target"| Aging
    Tumor{"Tumor"}
    DES -->|"therapeutic target"| Tumor
    Longevity{"Longevity"}
    DES -->|"therapeutic target"| Longevity
    DES -->|"associated with"| Ms
    MCU["MCU"]
    MCU -->|"activates"| DES
    SLC7A11["SLC7A11"]
    SLC7A11 -->|"activates"| DES
    BECN1["BECN1"]
    BECN1 -->|"activates"| DES
    GENES["GENES"]
    GENES -->|"therapeutic target"| DES
    AMPK["AMPK"]
    AMPK -->|"activates"| DES
    ABCB1["ABCB1"]
    ABCB1 -->|"associated with"| DES
    FAS["FAS"]
    FAS -->|"interacts with"| DES
    CASP8["CASP8"]
    CASP8 -->|"interacts with"| DES
    CASP6["CASP6"]
    CASP6 -->|"interacts with"| DES
    MITOCHONDRIAL_DYSFUNCTION["MITOCHONDRIAL DYSFUNCTION"]
    MITOCHONDRIAL_DYSFUNCTION -->|"activates"| DES
    APOPTOSIS["APOPTOSIS"]
    APOPTOSIS -->|"activates"| DES
    CANCER["CANCER"]
    CANCER -->|"associated with"| DES
    style DES fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (140)

TargetRelationTypeStr
Myofibrillar Myopathycausesdisease0.95
GJA1co_expressed_withgene0.80
SMOC2co_expressed_withgene0.80
DSPco_expressed_withgene0.80
Alsassociated_withdisease0.75

Incoming (56)

SourceRelationTypeStr
INFLAMMATIONcontributes_togene0.60
BECN1activatesgene0.60
BRCA1degradesentity0.60
SLC7A11activatesgene0.60
MACF1causesgene0.60

Targeting Hypotheses (29)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Competitive APOE4 Domain Stabilization Peptides 0.784 neurodegeneration APOE4 structural biology and therapeutic
Tau dysfunction destabilizes labile pool 0.750 neurodegeneration View
Exposed amyloidogenic segments (β-sheet propensity residues) 0.740 protein biochemistry Do chaperones selectively recognize path
Metabolic Inflexibility Precedes Transcriptional Reprogrammi 0.735 neurodegeneration What is the optimal therapeutic window f
Circulating Soluble PDGFRβ Reflects Pericyte Loss and Preced 0.720 - What blood-brain barrier permeability ch
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides 0.718 neurodegeneration Blood-brain barrier transport mechanisms
TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects S 0.708 synaptic biology Does SPP1-mediated synaptic engulfment r
H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properti 0.698 neurodegeneration How do pathological stress granules tran
Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurode 0.690 neurodegeneration Gap 006 analysis (archived stub)
Vascular mural cell degeneration precedes and exacerbates pa 0.637 Alzheimer's disease SEA-AD Single-Cell Analysis: Cell-Type V
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m 0.621 neurodegeneration Mitochondrial transfer between astrocyte
DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against T 0.604 neurodegeneration Should microtubule-stabilizing drugs be
Circulating Soluble PDGFRβ Reflects Pericyte Loss and Preced 0.600 - What blood-brain barrier permeability ch
TREM2-Driven Phagocytic Receptor Cascades Determine Mitochon 0.580 neurodegeneration What determines organelle-specific autop
Astrocyte cGAS/STING Activation Converts Protective into Des 0.580 neuroinflammation How does chronic cGAS/STING activation d
LYTL and JIP4-dependent lysosomal remodeling may show mutant 0.580 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
NAD+/SARM1 Axis Provides Metabolic Feedback Coupling Mitopha 0.578 neurodegeneration How do different organelle-specific auto
Post-Translational Modification Codes Determine Interaction 0.560 neurodegeneration What determines the specificity of RNA-p
CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial 0.530 pharmacology How can CNS-selective HDAC/DNMT inhibito
Circadian Clock Epigenetic Desynchronization Window 0.524 neurodegeneration What is the optimal therapeutic window d
Soluble GAG-Mimetic Peptides Compete with HSPG for Tau Seed 0.510 neurodegeneration Investigate prion-like spreading of tau
Synthetic Biology Approach: Designer Mitochondrial Export Sy 0.505 neurodegeneration Mitochondrial transfer between neurons a
C1q-Mediated Delivery of miR-33 Antisense Oligonucleotides f 0.489 molecular biology Is APOE4's reduced lipid binding pathoge
Liquid-Liquid Phase Separation (LLPS) Saturation Partitionin 0.461 neurodegeneration What determines the spatial organization
Kinase Inhibitor-C1q Structural Convergence for Bifunctional 0.458 neuroinflammation How does Alectinib, a kinase inhibitor,
Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA- 0.431 molecular neurobiology View
Age-driven synaptic gene silencing precedes neuronal loss in 0.390 Alzheimer's disease Allen Mouse Brain Aging Atlas: cross-age
Pulsatile Low-Dose Protocol to Prevent Receptor Desensitizat 0.380 - What is the optimal dosage and timing of
Multi-Clock Ensemble Discordance as a Parkinson's Disease Pr 0.377 - Epigenetic clocks as biomarkers for Alzh

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (19)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
GWAS of plasma NfL in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma pTau217 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
Dairy intake and dementia risk in Malmö Diet and Cancer cohort clinical Alzheimer's disease 0.950 0.00 Swedish community-based adults proposed N/A
GWAS of plasma pTau181 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma GFAP in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
KEEPS Continuation: Long-term effects of menopausal hormone therapy on clinical Alzheimer's disease 0.950 0.00 recently menopausal women with proposed N/A
GWAS of composite biomarker score exploratory Alzheimer's disease 0.900 0.00 human patients - East Asian co proposed N/A
RBG treatment in ApoE-/- atherosclerosis mouse model validation atherosclerosis 0.900 0.00 ApoE-/- mice proposed N/A
Irisin effects on angiogenesis in human endothelial cells exploratory bone fracture 0.900 0.00 human umbilical vein endotheli proposed N/A
APOE4 association with TDP-43 pathology in AD exploratory Alzheimer's disease 0.750 0.00 human patients proposed N/A
s:** - Biochemical binding assays measuring PROTAC selectivity for APO falsification Neurodegeneration 0.400 0.50 cell_line proposed $100,000
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv clinical Alzheimer's Disease 0.400 0.50 human proposed $6,550,000
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau clinical Alzheimer's Disease 0.400 0.50 cell_line proposed $180,000
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig clinical Alzheimer's Disease 0.400 0.50 human proposed $7,100,000
ApoE4 Function in Alzheimer's Disease validation Alzheimer's Disease 0.400 0.50 mouse proposed $360,000
Blood-Based Biomarker Panel for Early AD Detection clinical Alzheimer's Disease 0.400 0.50 cell_line proposed $220,000
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease validation Alzheimer's Disease 0.400 0.50 human proposed $2,730,000
Sex Differences in Alzheimer's Disease — mechanisms and therapeutic im clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] Litvinchuk A, Suh JH, Guo JL, Lin K, Dav Neuron 2024 1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] Maxine R Nelson, Peng Liu, Ayushi Agrawa Nature neuroscience 2023 1
Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] Calvier L, Herz J, Hansmann G JACC Basic Transl Sci 2022 1
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] Raulin AC, Doss SV, Trottier ZA, Ikezu T Mol Neurodegener 2022 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] Banik SM, Pedram K, Wisnovsky S, Ahn G, Nature 2020 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventin [PMID:30595089] Brophy ML, Dong Y, Tao H, Yancey PG, Son Circ Res 2019 1
Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical [PMID:28381441] Shinohara M, Tachibana M, Kanekiyo T, Bu J Lipid Res 2017 1
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] Cetindag AC, Schipke CG, Esselmann H, Kr The journal of prevention of A 2026 0
Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499] ["Barger S", "Moerman-Herzog A"] Frontiers in molecular neurosc 2026 0
Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990] Keller A Annual review of physiology 2026 0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha Frontiers in bioscience (Landm 2026 0
CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] ["Wang M", "Niu D", "Zhang Q", "Tang Y", International journal of biolo 2026 0
Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: [PMID:41921464] Catino F, Castellana F, Zupo R, Giannocc Artificial intelligence in med 2026 0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] Thedim M, Hu J, Maher M, Wiener-Kronish Br J Anaesth 2026 0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] Bae H, Song Z, Ali A, Sasaki T, Tesi N e Geroscience 2026 0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] Stern A, Linial M Geroscience 2026 0
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811] Wang Y, Zhang Z, Cao L, Huang S, Huang X J Ethnopharmacol 2026 0
Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710] Yang X, Xiao JH, Li X, Liu RM, Yuan Q J Ethnopharmacol 2026 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning DES in their description or question text

Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides

Score: 0.718 · neurodegeneration · 2026-04-02

## Mechanistic Overview Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides starts from the claim that modulating

TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from D

Score: 0.708 · synaptic biology · 2026-04-21

## Mechanistic Overview TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Re

H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properties

Score: 0.698 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The pathogenic mechanism underlying C9orf72-associated amyotrophic lateral sclero

Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurodegeneration in FTD-GR

Score: 0.690 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The pathogenesis of frontotemporal dementia with GRN mutations (FTD-GRN) involves

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.637 · Alzheimer's disease · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial deliver

Score: 0.621 · neurodegeneration · 2026-04-02

## Mechanistic Overview Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery starts from th

DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabili

Score: 0.604 · neurodegeneration · 2026-04-15

## Mechanistic Overview DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization starts fr

Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline

Score: 0.600 · unknown disease · 2026-04-26

Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blo

TREM2-Driven Phagocytic Receptor Cascades Determine Mitochondrial Antigen Presen

Score: 0.580 · neurodegeneration · 2026-04-21

**Molecular Mechanism and Rationale** The TREM2 (Triggering Receptor Expressed on Myeloid cells 2) signaling cascade re

Astrocyte cGAS/STING Activation Converts Protective into Destructive Neuroinflam

Score: 0.580 · neuroinflammation · 2026-04-21

## Mechanistic Overview Astrocyte cGAS/STING Activation Converts Protective into Destructive Neuroinflammation starts fr

LYTL and JIP4-dependent lysosomal remodeling may show mutant-selective amplifica

Score: 0.580 · neurodegeneration · 2026-04-24

A more mechanistic but less translationally mature possibility is that G2019S does not strongly alter total phospho-Rab

NAD+/SARM1 Axis Provides Metabolic Feedback Coupling Mitophagy to ER-Phagy

Score: 0.578 · neurodegeneration · 2026-04-21

## **Molecular Mechanism and Rationale** The NAD+/SARM1 axis represents a critical metabolic checkpoint that coordinate

Post-Translational Modification Codes Determine Interaction Specificity

Score: 0.560 · neurodegeneration · 2026-04-21

## Mechanistic Overview Post-Translational Modification Codes Determine Interaction Specificity starts from the claim th

CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial Priming Reversal

Score: 0.530 · pharmacology · 2026-04-21

## Mechanistic Overview CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial Priming Reversal starts from the cla

Circadian Clock Epigenetic Desynchronization Window

Score: 0.524 · neurodegeneration · 2026-04-21

## Mechanistic Overview Circadian Clock Epigenetic Desynchronization Window starts from the claim that modulating BMAL1/